← 返回

肝细胞癌的 NK 细胞免疫治疗:挑战与机遇

英文原题:NK cell-based immunotherapy for hepatocellular carcinoma: Challenges and opportunities.

查看英文原题

NK cell-based immunotherapy for hepatocellular carcinoma: Challenges and opportunities.

PubMed 2025/02/01(内容时间) Scand J Immunol Q3 · IF 2.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝细胞癌(HCC)仍然是全球最具挑战性的恶性肿瘤之一,其特征是显著的异质性、晚期诊断和治疗耐药。近年来,免疫检查点阻断(ICBs)和靶向免疫细胞疗法的出现标志着HCC治疗的重大进展。然而,这些现有疗法的临床疗效仍然有限,凸显了迫切需要新的突破。自然杀伤(NK)细胞是先天淋巴细胞家族的一个亚群,在抗肿瘤反应中显示出独特优势。越来越多的证据表明功能失调的NK细胞在HCC的发病机制和进展中起关键作用,因此大量研究致力于探索NK细胞作为HCC潜在治疗靶点。在本综述中,我们将概述NK细胞在正常肝脏免疫和HCC中的作用,随后详细讨论各种基于NK细胞的免疫疗法及其在HCC治疗中的潜在应用。

展开英文摘要原文

Hepatocellular carcinoma (HCC) remains one of the most challenging malignancies globally, characterized by significant heterogeneity, late-stage diagnosis, and resistance to treatment. In recent years, the advent of immune-checkpoint blockades (ICBs) and targeted immune cell therapies has marked a substantial advancement in HCC treatment.

However, the clinical efficacy of these existing therapies is still limited, highlighting the urgent need for new breakthroughs. Natural killer (NK) cells, a subset of the innate lymphoid cell family, have shown unique advantages in the anti-tumour response.

With increasing evidence suggesting the crucial role of dysfunctional NK cells in the pathogenesis and progression of HCC, considerable efforts have been directed toward exploring NK cells as a potential therapeutic target for HCC. In this review, we will provide an overview of the role of NK cells in normal liver immunity and in HCC, followed by a detailed discussion of various NK cell-based immunotherapies and their potential applications in HCC treatment.

论文信息

作者
Guo P、Zhong L、Wang T、Luo W、Zhou A、Cao D
单位
Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.China
文献类型
综述
期刊
Scandinavian journal of immunology2025 Feb
原文标识
PubMed 39934640 · DOI 10.1111/sji.13433